- In patients with uncontrolled type 2 diabetes (T2D), triple therapy with once-daily dapagliflozin (DAPA), saxagliptin (SAXA) and metformin (MET) significantly improved glycaemic control and reduced body weight compared with dual therapy with addition of either monocomponent to MET and was generalled well tolerated.
Why this matters
- Current treatment guidelines differ in perspectives on the most appropriate time to initiate and advance therapy with a combination of agents given simultaneously in patients with T2D.
- 832 patients with T2D were randomly assigned to receive DAPA+SAXA+MET (n=273), DAPA+MET (n=276) and SAXA+MET (n=283).
- Primary outcome: change in glycated hemoglobin (HbA1c) at 24 weeks.
- Secondary outcomes: the proportion of patients achieving HbA1c
- Funding: AstraZeneca.
- At 24 weeks, DAPA+SAXA+MET vs DAPA or SAXA+MET groups had a significant reduction in:
- HbA1c level (−1.03±0.06% vs −0.63±0.06% vs −0.69±0.06%; P<.0001 for both comparison>
- FPG level (−28±2 vs −20±2 mg/dL; P=.0135 vs −13±2 mg/dL; P<.0001>
- Long-term benefits of triple therapy vs dual therapy were not assessed.